COMPANY:

Visiopharm

P1, P1/2 | "The KEYNOTE-B84 study (NCT04815720) evaluated the safety and efficacy of pepinemab in combination with pembrolizumab as a first-line treatment for immunotherapy-naïve patients with R/M HNSCC. Biomarker studies conducted in patients with surgically resectable metastatic melanoma (NCT03769155) and HNSCC (NCT03690986) received neoadjuvant treatment with pepinemab/nivolumab/ipilimumab combinations compared to nivolumab or ipilimumab alone...Increased density and maturity of lymphoid aggregates correlated with disease control and longer progression-free survival (PFS). Conclusions Pepinemab, a Semaphorin 4D (SEMA4D) blocking antibody, in combination with ICB converts 'Cold' tumors to 'Hot' by inducing organized lymphoid aggregates."

"Evident announced on Tuesday an alliance with three partners to combine their technologies to deliver in the US an automated end-to-end workflow solution for pathology...The partnership among Evident, Corista, Sakura Finetek USA, and Visiopharm builds on two previous collaboration agreements. Under the terms of one of those deals, Evident and Concord, Massachusetts-based Corista combined their image management solutions with Denmark-based Visiopharm's image analysis and artificial intelligence tools to develop a high-end scanner with an image management system for that scanner."

"Paige...announced it is working with Visiopharm...to bring a wider range of AI products to doctors and patients. Visiopharm’s AI applications will be deployed and natively integrated into the Paige Platform to be accessed through FullFolio™, Paige’s AI-powered clinical worklist, and viewed within FullFocus®, Paige’s whole-slide image viewer. This deep integration offers users greater diagnostic efficiency and quality insights when reviewing IHC-stained slides and creates a seamless user experience for Visiopharm’s image analysis applications, to help pathologists deliver faster, more accurate and more reproducible cancer diagnoses."